Key Highlights

  • FULC closed at $3.14 on June 2, 2026, down 51.09%, after discontinuing its lead pociredir programme following FDA feedback that all PRC2 inhibitors carry equivalent malignancy risk.
  • The FDA's position was informed by Tazverik's global Withdrawal in March 2026 due to secondary blood cancers, leaving pociredir with no viable regulatory path forward despite strong efficacy data.
  • Fulcrum held $333.3 million in cash as of March 31, 2026, and has initiated a strategic review including potential sale or Merger Options.

The Collapse Explained

Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) closed at $3.14 on June 2, 2026, a loss of $3.28 or 51.09% on Volume of 32.77 million shares. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum is a clinical-stage biopharmaceutical company developing small molecule medicines that modulate gene expression to treat genetically defined rare diseases, with sickle cell disease as its primary focus. The selloff followed a June 1 announcement that the company was discontinuing its pociredir programme and initiating a strategic review.

The FDA Decision

On May 28, 2026, Fulcrum received meeting minutes from end-of-phase FDA interactions reflecting heightened regulator concerns about pociredir's benefit-risk profile. The FDA's position was shaped by the global withdrawal of Tazverik (tazemetostat), an Ipsen-developed PRC2 inhibitor cancer drug, in March 2026 following an unexpectedly high rate of secondary hematologic malignancies.

Fulcrum argued that pociredir, which targets the EED subunit of the PRC2 complex, was mechanistically distinct from tazemetostat, which targets the EZH2 subunit. The FDA considered this position but rejected it, concluding that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of which specific subunit is engaged. The agency cited pociredir's own preclinical malignancy observations as supporting this class-wide risk determination, leaving no viable regulatory path forward.

Class-Wide Risk: The PRC2 Problem

The FDA's refusal to differentiate between subunits within the PRC2 complex represents a significant regulatory precedent with implications beyond Fulcrum. Truist analyst Gregory Renza noted that the agency did not differentiate between sub-units, instead viewing the entire complex as carrying systemic cancer risk. Stifel analyst James Condulis described the discontinuation as surprising given pociredir's strong efficacy data and the high unmet need in sickle cell disease. The drug had demonstrated dose-dependent increases in fetal hemoglobin in the PIONEER Phase 1b trial, with no treatment-related serious adverse events reported, making the regulatory outcome particularly striking from a clinical standpoint.

The setback adds to a broader pattern of difficulties in sickle cell Drug Development. Pfizer withdrew its approved therapy Oxbryta and halted related studies in 2024 due to separate safety concerns.

Strategic Review and Cash Position

With pociredir discontinued, Fulcrum has initiated a comprehensive review of strategic alternatives including merger, Acquisition, Business combination, or other transactions involving the company or its Assets. Cost reduction measures are underway to preserve Capital. The company has not set a timeline for the review and does not intend to provide updates until a course of action is approved or disclosure is otherwise required.

The cash position provides meaningful optionality: Fulcrum held $333.3 million in cash, equivalents, and marketable securities as of March 31, 2026, a substantial sum relative to its post-crash Market Capitalisation of approximately $170 million, implying the stock is trading at a discount to net cash.

Conclusion

The 51.09% decline in FULC reflects the near-total destruction of the company's clinical value following the FDA's class-wide malignancy determination for PRC2 inhibitors. The remaining Investment thesis rests on the cash surplus, the strategic review outcome, and the possibility that Fulcrum's platform technology and pipeline assets attract a buyer at a premium to current levels. The gap between cash per share and Market Price makes the strategic review the single most material near-term catalyst.